Acrux Limited (AU:ACR) has released an update.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Acrux Limited has announced the commercial launch of its Nitroglycerin 0.4% ointment in the US market through its licensee, TruPharma, following FDA approval. The company is also offering a Share Purchase Plan to raise up to $2 million, available to eligible shareholders in Australia and New Zealand until December 18, 2024. With a strong track record in topical pharmaceuticals, Acrux continues to expand its product offerings globally.
For further insights into AU:ACR stock, check out TipRanks’ Stock Analysis page.
Trending Articles
- ‘The Nvidia of the Quantum Realm,’ Says Top Investor About Rigetti Computing Stock
- ‘Strike While the Iron Is Hot,’ Says Analyst About Tesla Stock
- ‘Load Up Before It Hits $204,’ Says William Stein About Nvidia Stock
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
